Gordon Christine Nayoma
Known title: DirectorCIK: 0001866667
Associated companies
Transaction History
| RDNT | ▼ Sell | Open Market | 1,500 | $92K | 6/10/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 3,000 | $184K | 6/7/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 4,994 | $0 | 1/9/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 3,000 | $97K | 11/27/2023 | View on chart |
| RDNT | ▼ Sell | Open Market | 4,884 | $138K | 5/23/2023 | View on chart |
| RDNT | ▲ Buy | Grant | 8,772 | $0 | 1/3/2023 | View on chart |
| RDNT | ▼ Sell | Open Market | 3,000 | $59K | 12/19/2022 | View on chart |
| RDNT | ▼ Sell | Open Market | 2,000 | $41K | 6/1/2022 | View on chart |
| RDNT | ▼ Sell | Open Market | 900 | $18K | 5/31/2022 | View on chart |
| RDNT | ▲ Buy | Grant | 6,897 | $0 | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.